9Suppliers
24Customers
1Debt Items
20Related Chains

Source-Backed Evidence Depth

Alvotech (ALVO) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

35Total relationships
1Distinct source URLs
5High confidence
0.678Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Alvotech Suppliers

TickerNameConfidenceEvidence
CONTRACT-MANUFACTURING-ORGANIZATIONS CONTRACT-MANUFACTURING-ORGANIZATIONS 90% We partly rely on third-party manufacturers (contract manufacturing organizations, or “CMOs”) to manufacture and supply our product candidates for our preclinical and clinical studies
THIRD-PARTY-CONTRACTORS THIRD-PARTY-CONTRACTORS 80% we rely on third parties to manufacture nonclinical and clinical supplies of our product candidates, to store critical components of our product candidates and perform various services related to the…
THIRD-PARTY-MANUFACTURING-VENDORS THIRD-PARTY-MANUFACTURING-VENDORS 80% one or more of our third-party manufacturing vendors may be found on regulatory inspection by the FDA or other comparable foreign regulatory authorities to be noncompliant with cGMP regulations
KMDA Kamada Ltd. 72% Reciprocal relationship from KMDA graph: Reciprocal relationship from ALVO graph: Reciprocal relationship from KMDA graph: License Application (BLA) of the product, in consideration for a $ million p…
LENZ LENZ Therapeutics, Inc. 72% Reciprocal relationship from LENZ graph: Item 1. Business Overview We are a commercial pharmaceutical company focused on the development and commercialization of innovative therapies to improve visio…
TEVA Teva Pharmaceutical Industries Limited 72% Reciprocal relationship from TEVA graph: Reciprocal relationship from ALVO graph: Reciprocal relationship from TEVA graph: nerics purchases, enabling each of them with significant bargaining power. A…
COLLABORATION-PARTNERS COLLABORATION-PARTNERS 70% our collaboration partners and contract manufacturers are subject to significant regulation with respect to manufacturing our product candidates
CONTRACT-MANUFACTURING-PARTNERS CONTRACT-MANUFACTURING-PARTNERS 70% Although we oversee our contract manufacturers, we cannot control the implementation of the manufacturing process by the contract manufacturing partners
THIRD-PARTY-VENDORS THIRD-PARTY-VENDORS 60% we cannot be certain that identifying and establishing relationships for these services would not result in significant delay or increased cost in the development of our product candidates or manufac…

Alvotech Customers

TickerNameConfidenceEvidence
ABT Abbott Laboratories 72% ion, variation or revocation of an approval. As a result, our business, financial condition and results of operations may be materially harmed. Additionally, if supply from one approved manufacturer …
ABT Abbott Laboratories 72% Reciprocal relationship from ABT graph: Reciprocal relationship from ALVO graph: Reciprocal relationship from ABT graph: Reciprocal relationship from ALVO graph: ion, variation or revocation of an ap…
KMDA Kamada Ltd. 72% Reciprocal relationship from KMDA graph: ch were received and accounted for as income through December 31, 2021, and for a minimum commitment of Takeda to acquire GLASSIA produced by the Company over…
LENZ LENZ Therapeutics, Inc. 72% Reciprocal relationship from LENZ graph: Item 1. Business Overview We are a commercial pharmaceutical company focused on the development and commercialization of innovative therapies to improve visio…
ALVOGEN-AZTIQ-ADALVO-LTD ALVOGEN-AZTIQ-ADALVO-LTD 62% ion, variation or revocation of an approval. As a result, our business, financial condition and results of operations may be materially harmed. Additionally, if supply from one approved manufacturer …
ALVOTECH-HOLDINGS ALVOTECH-HOLDINGS 62% essor Earn Out Shares”). Former OACB shareholders were granted a total of 1,250,000 Ordinary Shares subject to certain vesting conditions (“OACB Earn Out Shares”). Additionally, as part of the Busine…
ALVOTECH-HOLDINGS-S-A-OAKTREE-ACQUISITION-CORP ALVOTECH-HOLDINGS-S-A-OAKTREE-ACQUISITION-CORP 62% and cause misuse, disclosure, access, acquisition, loss, or damage to sensitive data, information systems, or other nosiness interruptions. We rely on third parties to operate critical business syste…
AMGEN-BOEHRINGER-INGELHEIM-GMBH AMGEN-BOEHRINGER-INGELHEIM-GMBH 62% ion, variation or revocation of an approval. As a result, our business, financial condition and results of operations may be materially harmed. Additionally, if supply from one approved manufacturer …
AMGEN-SAMSUNG-BIOEPIS-LTD AMGEN-SAMSUNG-BIOEPIS-LTD 62% ion, variation or revocation of an approval. As a result, our business, financial condition and results of operations may be materially harmed. Additionally, if supply from one approved manufacturer …
AMGN Amgen Inc. 62% Reciprocal relationship from AMGN graph: Reciprocal relationship from ALVO graph: ion, variation or revocation of an approval. As a result, our business, financial condition and results of operations…
ATP-HOLDINGS ATP-HOLDINGS 62% bility amounted to $ 8.7 million as of 31 December 2025. Service expenses with related parties are presented as “General and administrative expenses” or “Research and development expenses” in the con…
BIOCON-PHARMA-LTD BIOCON-PHARMA-LTD 62% ion, variation or revocation of an approval. As a result, our business, financial condition and results of operations may be materially harmed. Additionally, if supply from one approved manufacturer …
CELLTRION-HEALTHCARE-CO-LTD CELLTRION-HEALTHCARE-CO-LTD 62% ion, variation or revocation of an approval. As a result, our business, financial condition and results of operations may be materially harmed. Additionally, if supply from one approved manufacturer …
COMPANY-OAKTREE-ACQUISITION-CORP COMPANY-OAKTREE-ACQUISITION-CORP 62% or the year 27,919 ( 231,864 ) ( 551,731 ) Other comprehensive profit / (loss) Item that will be reclassified to profit or loss in subsequent periods: Exchange rate differences on translation of fore…
CSM-CLINICAL-SUPPLIES-MANAGEMENT-GMBH CSM-CLINICAL-SUPPLIES-MANAGEMENT-GMBH 62% with IFRS 3 B usiness Combinations and therefore was accounted for as an asset acquisition. Most of the fair value of the acquired assets is attributable to a single identifiable asset which is the i…
GLAS-AMERICAS-LLC GLAS-AMERICAS-LLC 62% if Teva fails to fulfill the minimum quantity of each product. Europe—STADA Alvotech has entered into a number of license and supply agreements with STADA pursuant to which we granted STADA licenses …
ILS-HOLDING-AG ILS-HOLDING-AG 62% with IFRS 3 B usiness Combinations and therefore was accounted for as an asset acquisition. Most of the fair value of the acquired assets is attributable to a single identifiable asset which is the i…
LEE-AG LEE-AG 62% with IFRS 3 B usiness Combinations and therefore was accounted for as an asset acquisition. Most of the fair value of the acquired assets is attributable to a single identifiable asset which is the i…
LEE-GROUP LEE-GROUP 62% int venture for gross proceeds of $18.0 million. Finance income and finance costs Finance income consists of changes in the fair value of derivative financial liabilities, interest income, and gain o…
OAKTREE-ACQUISITION-CORP OAKTREE-ACQUISITION-CORP 62% and cause misuse, disclosure, access, acquisition, loss, or damage to sensitive data, information systems, or other nosiness interruptions. We rely on third parties to operate critical business syste…
OAKTREE-ACQUISITION-HOLDINGS OAKTREE-ACQUISITION-HOLDINGS 62% and cause misuse, disclosure, access, acquisition, loss, or damage to sensitive data, information systems, or other nosiness interruptions. We rely on third parties to operate critical business syste…
PASSIVE-FOREIGN-INVESTMENT-COMPANY PASSIVE-FOREIGN-INVESTMENT-COMPANY 62% ‑prepayment provisions. As of 31 December 2025, $1,031.6 million was outstanding under the Secured Loan Facility. 2025 Senior Term Loan Facility On 31 December 2025, we entered into a $100 million Se…
SANDOZ-INTERNATIONAL-GMBH SANDOZ-INTERNATIONAL-GMBH 62% ion, variation or revocation of an approval. As a result, our business, financial condition and results of operations may be materially harmed. Additionally, if supply from one approved manufacturer …
UBS-SWITZERLAND-AG UBS-SWITZERLAND-AG 62% facility in Reykjavik. On 9 December 2022, the Group extinguished the assumed loans from Arion banki hf., with an outstanding balance of $ 30.9 million, with two new loans from Landsbankinn hf. for $…

Alvotech Debt Obligations

InstrumentDescriptionConfidenceEvidence
ALVO-DEBT Debt stack $1.5B 90% Market cache reports total debt of $1.5B.

Alvotech Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Alvotech.

Alvotech Ownership

HolderNameConfidenceEvidence
ALVO-OWNER-VANGUARD-CAPITAL-MANAGEMENT-LLC VANGUARD CAPITAL MANAGEMENT LLC 90% 13F overlay lists VANGUARD CAPITAL MANAGEMENT LLC as top holder; 57 tracked holders.

Alvotech Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
GIFLF Grifols, S.A. 100.00 2
TEVJF Teva Pharmaceutical Industries Limited 100.00 1 ['spend']
GIFOF Grifols, S.A. 100.00 2
IVA Inventiva S.A. 100.00 2
IINN Inspira Technologies Oxy B.H.N. Ltd. 100.00 2
NVS Novartis AG 100.00 2
FLGT Fulgent Genetics, Inc. 100.00 2
EXAS Exact Sciences Corp 100.00 2
AORT Artivion, Inc. 100.00 2
PSNL Personalis, Inc. 100.00 2
ITGR Integer Holdings Corporation 100.00 2
GCTK GlucoTrack, Inc. 100.00 2
LENZ LENZ Therapeutics, Inc. 100.00 1 ['customer', 'supplier']
NBP NovaBridge Biosciences 100.00 2
GRAL GRAIL, Inc. 100.00 2
GRFS Grifols, S.A. 100.00 2
SVA Sinovac Biotech Ltd. 100.00 2
GIKLY Grifols, S.A. 100.00 2
AMGN Amgen Inc. 100.00 1 ['customer']
SNYNF Sanofi 100.00 2
🔐
ALVO
Unlock ALVO Supply Chain Data
Verified relationships include:
CONTRACT-MANUFACTURING-ORGANIZATIONSCONTRACT-MANUFACTURING-OR…Supplier90%
THIRD-PARTY-CONTRACTORSTHIRD-PARTY-CONTRACTORSSupplier80%
ABTAbbott LaboratoriesCustomer72%
ABTAbbott LaboratoriesCustomer72%
+31 more relationships locked
Subscribe — View plans →